Heart failure & cardiomyopathiesSecondary analysis
Finerenone and NYHA Functional Class in Heart Failure
- Secondary analysis of the FINEARTS-HF randomised trial
- prespecified analysis
Authors' conclusion
In this FINEARTS-HF analysis, finerenone reduced clinical outcomes and improved patient-reported health status in HF with mildly reduced or preserved ejection fraction irrespective of baseline NYHA functional class.
Study context
- Population
- Heart failure (HF) with mildly reduced or preserved EF
- Participants
- 4,146 vs 1,854
- Comparison
- Finerenone vs placebo by baseline NYHA class
- NYHA IIn = 4,146reference
- NYHA III/IVn = 1,854
- Primary endpoint
- CV death and total HF events
Primary result
As reported in the abstract
CV death and total HF events: finerenone effect by NYHA class
Adjusted rate ratio
1.28
95% CI 1.11–1.46
P < 0.001
By group
NYHA III/IV
4.5 per 100 person-years
ARR with finerenone
NYHA II
2.0 per 100 person-years
ARR with finerenone
NYHA III/IV vs NYHA II
adjusted rate ratio 1.28 (95% CI 1.11–1.46); P < 0.001
- Finerenone consistently reduced the primary endpoint irrespective of baseline NYHA class
- P for interaction = 0.54
Secondary outcomes
KCCQ-Total Symptom Score benefit, by NYHA class · 12 months
- Benefits of finerenone consistent irrespective of NYHA class
- P for interaction = 0.93
Change in NYHA functional class · 12 months
- NYHA class improved similarly in finerenone and placebo arms
Original publication
Finerenone and NYHA Functional Class in Heart Failure. JACC Heart Fail. Published 2 April 2025. doi:10.1016/j.jchf.2025.03.007
Summarised from the published abstract; every number is checked against it